A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Trial to Evaluate the Immunogenicity and Safety of a 24-Valent Pneumococcal Conjugate Vaccine (PCV24, RZ700) Following Vaccination in Adults Aged 18 Years and Older
A phase III clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is a multicenter, randomized, double-blind and active-controlled phase III clinical trial.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
A Phase Ⅲ clinical trial of the 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older. The study's objective is to evaluate the safety and immunogenicity of PCV24. The active control vaccine is a 23-valent pneumococcal polysaccharide vaccine (PPSV23) produced by Merck & Co.A total of 1,260 participants will be enrolled, including 756 participants aged 65-74 years, who will be randomized 1:1 to receive one dose of PCV24 or PPSV23, and 84 participants aged 75 years and older, who will be randomized 1:1 to receive one dose of PCV24 or PPSV23. In addition, 420 participants aged 18-64 years will receive one dose of PCV24.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Tao Huang, Bachelor
- Numero di telefono: 86+15084736658
- Email: ymlc01@hnedc.com
Luoghi di studio
-
-
-
Shanghai, Cina
- Shanghai Center for Disease Control and Prevention
-
Contatto:
- Xiaodong Sun
- Numero di telefono: 86+13601791418
- Email: sunxiaodong1380@126.com
-
-
Hunan
-
Changsha, Hunan, Cina
- Hunan Center for Disease Control and Prevention
-
Contatto:
- Tao Huang
- Numero di telefono: 86+15084736658
- Email: ymlc01@hnedc.com
-
-
Yunan
-
Baoshan, Yunan, Cina, 678000
- Baoshan Second People's Hospital
-
Contatto:
- Yanhong Jiang
- Numero di telefono: 86+18725329929
- Email: 18725329929@139.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
1)Aged 18 years and older, able to provide valid legal identification; 2)Capable of understanding the clinical trial procedures, voluntarily agreeing to participate, and signing the informed consent form; 3)Willing and able to comply with the requirements of the clinical trial protocol and to attend all scheduled visits; 4) Male participants and female participants of childbearing potential agreeing to use effective contraception within 6 months after vaccination (effective contraceptive measures include: oral contraceptives, injectable or implanted contraceptives, sustained-release topical contraceptives, hormone patches, intrauterine device (IUD), sterilization, abstinence, and condoms (for males)); the rhythm method, coitus interruptus, and emergency contraception are not acceptable contraceptive measures; 5) Axillary temperature ≤37.0°C on the day of enrollment. Exclusion Criteria:
- Previous vaccination with any pneumococcal vaccine, or a history of invasive pneumococcal disease caused by Streptococcus pneumoniae within 3 years before enrollment;
- History of any severe allergic reaction, such as anaphylactic shock, allergic laryngeal edema, angioneurotic edema, dyspnea, severe urticaria, allergic purpura, or local allergic necrotizing reaction (Arthus reaction); or a history of thrombocytopenic purpura; or known allergy to any component of the investigational vaccine (aluminum phosphate adjuvant, phenol, sodium chloride, succinic acid, polysorbate 80, or water for injection);
- Lactating or pregnant women, or women of childbearing potential planning to become pregnant during the study period; women of childbearing potential who have not used effective contraception from the end of their last menstrual cycle until enrollment; or women of childbearing potential with a positive urine pregnancy test at enrollment (sensitivity 25 mIU/mL for β-hCG);
- Diagnosed with congenital or acquired immunodeficiency; or other diseases affecting immune function (such as asplenia, functional asplenia, and asplenia or splenectomy due to any cause).
- Long-term (continuous ≥14 days) use of immunosuppressants or other immunomodulatory drugs within 3 months before enrollment or planned during the study period [e.g., systemic corticosteroids ≥14 days at a dose of ≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent; topical use is permitted (e.g., ointments, eye drops, inhalers, or nasal sprays), provided the dose does not exceed the recommended dosage in the package insert];
- Severe cardiovascular disease, such as myocardial infarction (acute onset within 6 months before signing the informed consent form), cardio-cerebrovascular syndrome, severe arrhythmia, unstable angina, or poorly controlled arrhythmia;
- Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg measured at the screening physical examination on site; for participants with a history of hypertension, enrollment is permitted only if confirmed by inquiry that blood pressure has been stable over the past 3 months and there have been no obvious cardio-cerebrovascular disease-related symptoms in the past 2 weeks;
- Receipt of blood or blood-related products, or immunoglobulin within 3 months before enrollment (except hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin);
- Vaccination with any other inactivated vaccine within 7 days before vaccination, or with any live attenuated vaccine within 14 days before vaccination;
- Acute illness within 3 days before vaccination, or acute exacerbation of a chronic disease, or use of antipyretic/analgesic drugs (excluding medications used to control pre-existing conditions that, in the investigator's judgment, would not affect the evaluation of study results, such as aspirin used for antiplatelet aggregation) or anti-allergic drugs;
- Active tuberculosis, active viral hepatitis, or HIV infection; or other active infectious diseases that, in the judgment of the investigator, may affect the safety of vaccination or interfere with the assessment of immunogenicity;
- Severe neurological diseases (e.g., uncontrolled epilepsy), or a history of psychiatric disorders affecting normal behavior, or a family history of such diseases with a hereditary tendency;
- Diagnosed thrombocytopenia, any coagulation disorder, or receiving anticoagulant therapy, or other conditions contraindicating intramuscular injection;
- Severe chronic diseases or chronic diseases in an uncontrolled progressive stage (e.g., uncontrolled diabetes, severe hepatic or renal disease), excluding a history of cured or stable, well-controlled tumors (except malignant tumors);
- Use of another investigational or unregistered product (drug or vaccine) within 1 month before enrollment, or current participation in another clinical trial, or planned participation in another clinical trial during the study period;
- Any other condition that, in the opinion of the investigator, may interfere with the evaluation of the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Experimental group 1
378 participants aged 65-74 years will be randomly assigned to receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose. |
Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL |
|
Comparatore attivo: Active control group 1
378 participants aged 65-74 years will be randomly assigned to receive PPSV23. The route of administration is intramuscular injection into the lateral deltoid muscle of the upper arm. The immunization schedule is 1 dose. |
One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.
Altri nomi:
|
|
Sperimentale: Experimental group 2
42 participants aged 75 years and older will be randomly assigned to receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose. |
Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL |
|
Comparatore attivo: Active control group 2
42 participants aged 75 years and older will be randomly assigned to receive PPSV23. The route of administration is intramuscular injection into the lateral deltoid muscle of the upper arm. The immunization schedule is 1 dose. |
One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.
Altri nomi:
|
|
Sperimentale: Experimental group 3
420 participants aged 18-64 years will receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose. |
Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).
Lasso di tempo: 0~30 days after vaccination
|
The geometric mean titers (GMTs) of 24 vaccine serotype-specific MOPA antibodies at 0 days and 30 days after vaccination in participants aged 65 years and older, measured by the multiplexed opsonophagocytic assay (MOPA). |
0~30 days after vaccination
|
|
Proportional participants with the MOPA titer rise of 4-fold or higher
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 65 years and older whose MOPA antibody titers show a 4-fold or greater increase from the pre-immunization baseline at 30 days after vaccination, for each of the 24 vaccine serotypes. |
0~30 days after vaccination
|
|
Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).
Lasso di tempo: 0~30 days after vaccination
|
The geometric mean titers (GMTs) of the 24 vaccine serotype-specific MOPA antibodies at 0 day and 30 days after vaccination in participants aged 18-64 years, measured by the multiplexed opsonophagocytic assay (MOPA). |
0~30 days after vaccination
|
|
Incidence of adverse events
Lasso di tempo: 0-30 minutes after vaccination
|
The incidence of any local and systemic adverse events occurring within 30 minutes after vaccination. |
0-30 minutes after vaccination
|
|
Incidence of solicited adverse events
Lasso di tempo: 0-7 days after vaccination
|
The incidence of solicited adverse events occurring within 7 days after vaccination. |
0-7 days after vaccination
|
|
Incidence of unsolicited adverse events
Lasso di tempo: 0-30 days after vaccination
|
The incidence of unsolicited adverse events occurring within 30 days after vaccination. |
0-30 days after vaccination
|
|
Incidence of serious adverse events (SAE)
Lasso di tempo: 0-6 months after vaccination
|
The incidence of serious adverse events (SAE) occurring within 6 months after vaccination. |
0-6 months after vaccination
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Seropositivity rate as measured using MOPA
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 65 years and older with MOPA antibody titers ≥1:8 for each of the 24 vaccine serotypes, detected by MOPA 30 days after immunization. Unit of measure: percentage of participants. |
0~30 days after vaccination
|
|
Increase rate of as measured using MOPA
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 65 years and older whose MOPA antibody titer shows a 2-fold or greater increase from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants. |
0~30 days after vaccination
|
|
The geometric mean fold rise (GMFR) of MOPA antibody titers
Lasso di tempo: 0~30 days after vaccination
|
The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific MOPA antibody titers from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 65 years and older. |
0~30 days after vaccination
|
|
Seropositivity rate of IgG antibodies
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 65 years and older with IgG geometric mean concentration (GMC) ≥0.35 µg/mL for each of the 24 vaccine serotypes, detected by ELISA 30 days after immunization. Unit of measure: percentage of participants. |
0~30 days after vaccination
|
|
Positive conversion rate of IgG antibodies
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 65 years and older whose IgG antibody concentration shows a 2-fold or greater increase (positive conversion) from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants. |
0~30 days after vaccination
|
|
The IgG geometric mean concentration (GMC) of each serotype
Lasso di tempo: 0~30 days after vaccination
|
The geometric mean concentration (GMC) of 24 vaccine serotype-specific IgG antibodies detected by ELISA 30 days after immunization in participants aged 65 years and older. |
0~30 days after vaccination
|
|
The geometric mean fold rise (GMFR) of IgG antibodies
Lasso di tempo: 0~30 days after vaccination
|
The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific IgG antibody concentration from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 65 years and older. |
0~30 days after vaccination
|
|
Seropositivity rate of multiplexed opsonophagocytic assay (MOPA) antibodies
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 18-64 years with MOPA antibody titer ≥1:8 for each of the 24 vaccine serotypes, detected by MOPA 30 days after immunization. Unit of measure: percentage of participants. |
0~30 days after vaccination
|
|
Increase rate of multiplexed opsonophagocytic assay (MOPA) antibodies
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 18-64 years whose MOPA antibody titer shows a 2-fold or greater increase from the pre-immunization baseline (2-fold increase rate), and the percentage whose MOPA antibody titer shows a 4-fold or greater increase from the pre-immunization baseline (4-fold increase rate), at 30 days after immunization for each of the 24 vaccine serotypes. Unit of measure: percentage of participants. |
0~30 days after vaccination
|
|
The geometric mean fold rise (GMFR) of multiplexed opsonophagocytic assay (MOPA) antibodies
Lasso di tempo: 0~30 days after vaccination
|
The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific MOPA antibody titer from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 18-64 years. |
0~30 days after vaccination
|
|
Seropositivity rate of IgG antibodies
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 18-64 years with IgG antibody concentration ≥0.35 µg/mL for each of the 24 vaccine serotypes, detected by ELISA 30 days after immunization. Unit of measure: percentage of participants. |
0~30 days after vaccination
|
|
Positive conversion rate of IgG antibodies
Lasso di tempo: 0~30 days after vaccination
|
The percentage of participants aged 18-64 years whose IgG antibody concentration shows a 2-fold or greater increase (positive conversion) from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants. |
0~30 days after vaccination
|
|
The geometric mean concentration (GMC) of specific IgG antibodies
Lasso di tempo: 0~30 days after vaccination
|
The geometric mean concentration (GMC) of 24 vaccine serotype-specific IgG antibodies detected by ELISA 30 days after immunization in participants aged 18-64 years. |
0~30 days after vaccination
|
|
The geometric mean fold rise (GMFR) of specific IgG antibodies
Lasso di tempo: 0~30 days after vaccination
|
The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific IgG antibody concentration from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 18-64 years. |
0~30 days after vaccination
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- RNCVCT7A003
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .